The Committees jointly supported, by a vote of 22-Yes to 1-No, the safety and efficacy of talimogene laherparepvec (T-Vec), submitted by Amgen, Inc. (Amgen). T-Vec is an oncolytic immunotherapy proposed for the treatment of patients with injectable regionally or distantly metastatic melanoma.
Back to All Events
Earlier Event: April 15Cardiovascular and Renal Drugs Advisory Committee (CRDAC)
Later Event: May 12Pulmonary-Allergy Drugs Advisory Committee